2019 Symposium

2018 Symposium

2017 Symposium

2016 Symposium

2015 Symposium

2015 Agenda and Bios

2015 Symposium Photos

Previous Symposia

2019 Featured Talks » Panel Discussion: Solid Tumors

Panel Discussion: Solid Tumors/b>

Chair: Rebecca Shatsky, MD
UC San Diego Moores Cancer Center

Rana McKay, MD, UC San Diego Moores Cancer Center
Derek Johnston, Patient Advocate
José Ricardo Pérez, MD, Exelixis
Ewa Carrier, MD, Fibrogen

Rebecca Shatsky, MD
Assistant Clinical Professor
UC San Diego Moores Cancer Center

Rebecca A. Shatsky is a board-certified medical oncologist who specializes in treating breast cancer. She uses numerous forms of therapy such as chemotherapy, hormone therapy, biological therapy and targeted therapy to offer the best treatment options for her patients.

As a medical oncologist at an academic medical center, Dr. Shatsky teaches residents and fellows at UC San Diego School of Medicine. She conducts breast cancer research at Moores Cancer Center at UC San Diego Health and is currently working on launching a phase I clinical trial that focuses on the treatment of locally advanced and metastatic breast cancer. Her research work, funded by a grant from the Breast Cancer Research Foundation, targets the ROR1 receptor in breast cancer treatment.

Her work has been published in Annals of Emergency Medicine, Cancer Treatment Reviews and Personalized Medicine in Oncology, among others. She presented on the topic of detecting molecular alternations in breast cancer at the San Antonio Breast Cancer Symposium.

Dr. Shatsky completed a hematology/oncology fellowship at UC San Diego School of Medicine, where she was recognized as an outstanding oncology fellow by the National Comprehensive Cancer Network. She completed her residency at UCLA David Geffen School of Medicine and earned her medical degree from the Keck School of Medicine of University of Southern California. She is board certified in internal medicine, hematology and medical oncology.

Dr. Shatsky is a member of the American Association for Cancer Research, the American Society of Clinical Oncology, and the American Society of Hematology.

Outside of work, she enjoys spending time with her husband Chris and daughter, Bailey, hiking and traveling.

Rana McKay, MD
Assistant Professor of Medicine
UC San Diego Moores Cancer Center

Rana R. McKay, MD, is a board-certified medical oncologist who specializes in treating people with genitourinary (urologic) cancers, including bladder cancer, kidney cancer, prostate cancer and testicular cancer. Dr. McKay is part of the urologic cancer unit at UC San Diego Health’s Moores Cancer Center, where she works alongside a multidisciplinary team to provide patients with highly specialized care.

As an Assistant Professor in the Department of Medicine, Dr. McKay instructs medical students, residents, and fellows at UC San Diego School of Medicine. Her primary research interests include the design and implementation of clinical trials to advance the treatment of patients with genitourinary cancers. As a clinical investigator, she is committed to advancements in cancer care that will improve the lives of cancer patients. Furthermore, she is interested in understanding mechanisms of response and resistance to specific cancer therapies. Her work has appeared in peer-reviewed publications such as the Journal of Clinical Oncology, Clinical Cancer Research, and Cancer, among others. Additionally, Dr. McKay serves as the Genitourinary Oncology Disease Team Co-Leader. She is responsible for coordinating clinical, research, and educational programing within the Genitourinary Oncology Disease Team including strategies to improve the delivery of patient care and expand the clinical and translational research portfolio within the group.

Before joining UC San Diego Health in 2016, Dr. McKay was a medical oncologist at the Dana-Farber/Brigham and Women's Cancer Center in Boston and an Assistant Professor at Harvard Medical School.

Dr. McKay completed a fellowship in oncology/hematology at the Dana-Farber Cancer Institute, Harvard Medical School. She completed a residency in internal medicine at John Hopkins School of Medicine in Baltimore, Maryland. Dr. McKay earned her medical degree at the University of Florida College of Medicine in Gainesville, Florida. She is board-certified in internal medicine and medical oncology.

Dr. McKay is a member of the American Society of Clinical Oncology and the American Association for Cancer Research.

José Ricardo Pérez, MD
Executive Medical Director, Medical Affairs

Dr. Jose Ricardo Perez has served in leadership positions in academia, healthcare, and pharmaceuticals. Currently he is an Executive Medical Director of Medical Affairs at Exelixis, responsible for Genitourinary Cancers and Sarcomas. In previous roles he created and lead the world’s largest expanded access protocol for patients with myelofibrosis using innovative therapies in collaboration with clinicians in multiple centers of excellence in major European centers. Formerly, Dr.Perez practiced as a Medical Doctor, Specialist in Internal Medicine and in Clinical Oncology in Venezuela taking care of patients with Cancer. With an active participation in clinical trials he contributed in the development of safe and more effective therapies to patients with diverse types of cancer.

Ewa Carrier, MD
Executive Director of Clinical Development

Dr. Ewa Carrier is Executive Director of Clinical Development at FibroGen, Inc. Prior to FibroGen, she was VP of Medical Affairs at NovaRx Corporation, and Director of Clinical Development and Medical Affairs at Boehringer Ingelheim, developing cancer vaccines and first-in-class PLK inhibitor. Dr. Carrier is a board certified hematologist/oncologist and transplant physician, who spent most of her career in academia, where she trained at Stanford and held a faculty position at the University of California, San Diego from 1997-2012 in the Hematology and Transplant Division. She developed unique mouse model of prenatal transplantation and contributed to the development of reduced toxicity transplants for patients with hematologic malignancies. She also developed a novel patented technology for developing off shelf human red blood cells. She is member of ASH, ASCO and AACR, and is currently focused on the development of new therapies for cancer.